Dawnrays Pharmaceutical (Holdings) Limited

SEHK:2348 Stock Report

Mkt Cap: HK$2.0b

We’ve recently updated our valuation analysis.

Dawnrays Pharmaceutical (Holdings) Valuation

Is 2348 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2348?

Other financial metrics that can be useful for relative valuation.

2348 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.7x
Enterprise Value/EBITDA2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 2348's PE Ratio compare to its peers?

The above table shows the PE ratio for 2348 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average8.6x
2633 Jacobson Pharma
8xn/aHK$1.9b
1681 Consun Pharmaceutical Group
4.5x9.8%HK$3.3b
3737 Zhongzhi Pharmaceutical Holdings
13.4xn/aHK$967.2m
2877 China Shineway Pharmaceutical Group
8.4x9.4%HK$5.6b
2348 Dawnrays Pharmaceutical (Holdings)
4.8xn/aHK$2.0b

Price-To-Earnings vs Peers: 2348 is good value based on its Price-To-Earnings Ratio (4.8x) compared to the peer average (8.6x).


Price to Earnings Ratio vs Industry

How does 2348's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.8%
n/an/an/a

Price-To-Earnings vs Industry: 2348 is good value based on its Price-To-Earnings Ratio (4.8x) compared to the Hong Kong Pharmaceuticals industry average (10.7x)


Price to Earnings Ratio vs Fair Ratio

What is 2348's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2348 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio4.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 2348's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of 2348 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2348 (HK$1.34) is trading below our estimate of fair value (HK$11.3)

Significantly Below Fair Value: 2348 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies